felin
infecti
periton
viru
fipv
replic
macrophagesmonocyt
induc
tumor
necrosi
factor
tnf
alpha
product
tnfalpha
produc
involv
aggrav
patholog
fip
previous
report
prepar
felin
tnfalpha
ftnfalpha
neutral
mous
monoclon
antibodi
antiftnfalpha
mab
antiftnfalpha
mab
confirm
inhibit
follow
ftnfalphainduc
condit
vitro
present
studi
investig
whether
mab
improv
fip
symptom
surviv
rate
experiment
fipvinocul
spf
cat
progress
fip
prevent
cat
treat
mab
wherea
cat
develop
fip
placebo
control
group
plasma
vascular
endotheli
growth
factor
level
improv
administr
mab
peripher
lymphocyt
count
also
recov
result
strongli
suggest
antiftnfalpha
antibodi
effect
treatment
fip
felin
infecti
periton
viru
fip
viru
fipv
felin
coronaviru
fcov
famili
coronavirida
caus
fatal
diseas
call
fip
wild
domest
cat
speci
sever
organ
includ
liver
lung
spleen
serosa
kidney
eye
central
nervou
system
affect
cat
develop
fip
format
lesion
organ
accompani
necrosi
pyogen
granulomat
inflamm
pedersen
pleural
effus
ascit
fluid
report
accumul
cat
macrophagesmonocyt
play
import
role
pathogenesi
fip
exampl
differ
prolifer
viru
macrophagesmonocyt
shown
relat
differ
pathogen
felin
enter
coronaviru
fecv
fipv
dewerchin
et
al
stoddart
scott
fecv
fipv
serolog
distinguish
howev
fecv
infect
normal
asymptomat
cat
recent
report
fecv
fipv
may
distinguish
base
base
sequenc
orf
gene
gene
bankwolf
et
al
licitra
et
al
pedersen
et
al
porter
et
al
tumor
necrosi
factor
tnf
alpha
bind
cell
surfac
tnf
receptor
tnfr
induc
variou
physiolog
activ
vandenabeel
et
al
reinhard
et
al
exampl
bind
cell
surfac
caspas
activ
induc
apoptosi
bind
cell
surfac
transcript
factor
nfkb
cjun
activ
promot
cell
prolifer
induc
express
cytokin
involv
immun
inflamm
faustman
davi
tracey
et
al
tnfalpha
play
critic
role
mani
aspect
immun
howev
excess
product
tnfalpha
lead
acut
inflamm
immun
system
abnorm
human
anim
involv
tnfalpha
aggrav
symptom
rheumatoid
arthriti
psoriasi
inflammatori
bowel
diseas
report
kollia
et
al
brota
et
al
wang
fu
moreov
previou
studi
describ
aggrav
patholog
viral
infect
human
immunodefici
viru
influenza
viru
herp
simplex
viru
hsv
dengu
viru
infect
due
increas
tnfalpha
product
fauci
mauri
poli
et
al
uchid
et
al
yen
et
al
previous
show
viru
replic
macrophagesmonocyt
induc
tnfalpha
product
tnfalpha
produc
involv
aggrav
patholog
fip
tnfalpha
produc
fipvinfect
macrophag
involv
lymphopenia
increas
level
cellular
receptor
serotyp
ii
fipv
aminopeptidas
n
apn
takano
et
al
takano
et
al
also
report
neutrophil
apoptosi
cat
fip
inhibit
tnfalpha
find
suggest
neutrophilia
cat
fip
due
tnfalphainduc
neutrophil
surviv
takano
et
al
human
antitnf
agent
shown
therapeut
effect
tnfrelat
diseas
rheumatoid
arthriti
inflammatori
bowel
diseas
tracey
et
al
antitnf
agent
previous
shown
effect
treatment
fatal
viral
infect
boivin
et
al
report
surviv
rate
mice
hsv
enceph
improv
administr
antitnfalpha
antibodi
research
veterinari
scienc
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
r
v
c
antitnfalpha
agent
also
expect
improv
symptom
fip
caus
viral
infect
addi
ishida
previous
describ
prepar
felin
tnfalpha
ftnfalpha
neutral
mous
monoclon
antibodi
antiftnfalpha
mab
anti
ftnfalpha
mab
exhibit
high
neutral
activ
recombin
natur
tnfalpha
confirm
inhibit
follow
ftnfalphainduc
condit
vitro
increas
surviv
rate
neutrophil
cat
fip
ii
apn
mrna
express
macrophag
iii
apoptosi
felin
tlymphocyt
cell
line
doki
et
al
present
studi
confirm
efficaci
ftnfalpha
mab
treatment
fip
vivo
spf
cat
experiment
inocul
fipv
treat
antiftnfalpha
mab
improv
fip
symptom
surviv
rate
investig
hybridoma
cell
produc
mab
maintain
dulbecco
modifi
eagl
minimum
essenti
medium
supplement
fc
uml
benzylpenicillin
potassium
streptomycin
sulfat
murin
sarcoma
cell
atcc
maintain
rpmi
growth
medium
supplement
fc
uml
benzylpenicillin
potassium
streptomycin
sulfat
polybren
murin
sarcoma
cell
obtain
american
type
cultur
collect
type
ii
fipv
strain
grown
feli
catu
whole
cell
fipv
strain
suppli
dr
c
horzinek
state
univers
utrecht
netherland
anti
ftnfalpha
mab
describ
previous
doki
et
al
mab
neutral
activ
recombin
ftnfalpha
natur
ftnfalpha
phycoerythrin
pe
conjug
antifelin
mab
southern
biotechnolog
associ
inc
usa
fluorescein
isothiocyan
fitc
conjug
antifelin
mab
southern
biotechnolog
associ
inc
usa
use
flow
cytometri
analysi
measur
number
lymphocyt
mab
purifi
hybridoma
cultur
supernat
protein
g
sepharos
ge
healthcar
usa
accord
product
manual
purif
buffer
mab
exchang
phosphatebuff
salin
pb
ph
amicon
centrifug
filter
devic
nmwl
millipor
usa
concentr
purifi
mab
assay
bradford
method
neutral
activ
purifi
mab
confirm
neutral
test
tnfalpha
use
cell
previous
describ
doki
et
al
purifi
mab
neutral
activ
ngml
recombin
ftnfalpha
six
spf
cat
randomli
assign
two
experiment
group
cat
bred
laboratori
maintain
temperaturecontrol
isol
facil
accord
experiment
schedul
indic
fig
fipv
strain
tcid
ml
inocul
subcutan
cat
pb
mab
mgkg
intraven
administ
group
b
respect
week
viru
inocul
cat
examin
daili
clinic
sign
bodi
temperatur
weight
measur
blood
collect
weekli
use
heparin
syring
viru
inocul
complet
differenti
cell
count
measur
fip
diagnos
confirm
upon
postmortem
examin
reveal
periton
pleural
effus
pyogranuloma
major
organ
protocol
experi
present
studi
use
cat
approv
ethic
committe
kitasato
univers
school
veterinari
medicin
approv
blood
collect
cat
use
heparin
syring
centrifug
rpm
min
supernat
use
plasma
sampl
plasma
sampl
store
day
analysi
measur
plasma
agp
plasma
concentr
agp
determin
felin
ag
plate
institut
metabol
ecosystem
lab
japan
accord
manufactur
protocol
plasma
concentr
vegf
determin
human
vegf
elisa
kit
r
system
uk
accord
manufactur
protocol
elisa
kit
detect
primarili
felin
vegf
isoform
koga
et
al
measur
lymphocyt
count
use
flow
cytometri
analysi
heparin
blood
ml
dilut
pb
subject
ficollhypaqu
axisshield
poc
norway
densiti
gradient
centrifug
min
pbmc
layer
collect
wash
twice
pb
resuspend
ice
cold
pb
contain
nan
cellsml
cell
incub
peconjug
antifelin
mab
fitcconjug
antifelin
mab
min
wash
cell
store
fluoresc
buffer
prior
analysi
flow
cytomet
cytom
beckman
coulter
usa
small
lymphocyt
lymphoblast
popul
gate
basi
cell
size
granular
forward
side
scatter
sampl
event
record
percentag
lymphocyt
popul
calcul
absolut
lymphocyt
count
determin
complet
blood
count
differenti
cell
count
percentag
lymphocyt
popul
data
two
group
analyz
student
test
increas
plasma
agp
vegf
level
report
cat
develop
fip
duthi
et
al
paltrinieri
et
al
paltrinieri
et
al
takano
et
al
order
determin
therapeut
effect
antiftnfalpha
mab
chang
plasma
agp
vegf
level
fipv
inocul
administr
mab
investig
increas
agp
vegf
level
note
day
fipv
inocul
placebotr
group
mab
cat
group
b
fig
signific
differ
note
agp
vegf
level
group
b
day
fipv
inocul
day
administr
mab
howev
level
significantli
lower
group
b
group
day
fipv
inocul
day
administr
mab
chang
neutrophil
count
fipv
inocul
administr
mab
investig
neutrophil
count
slightli
decreas
day
viru
challeng
recov
almost
normal
level
day
fig
rate
neutrophil
differenti
cell
count
shown
fig
group
rate
neutrophil
increas
fipv
inocul
maintain
high
level
day
thereaft
contrast
cat
no
rate
neutrophil
increas
day
fipv
inocul
stabil
day
administr
mab
day
fipv
inocul
thereaft
cat
treat
mab
still
develop
fip
rate
neutrophil
stabl
day
fipv
inocul
rapidli
increas
day
fipv
inocul
chang
peripher
lymphocyt
count
fipv
inocul
administr
mab
investig
peripher
lymphocyt
markedli
decreas
cat
day
viru
challeng
fig
cat
no
count
start
increas
day
administr
mab
day
fipv
inocul
recov
prefipv
inocul
level
day
administr
mab
day
fipv
inocul
contrast
peripher
lymphocyt
count
cat
develop
fip
group
recov
even
day
viru
challeng
remain
low
develop
fip
cat
treat
mab
still
develop
fip
peripher
lymphocyt
count
temporarili
recov
day
administr
mab
day
fipv
inocul
markedli
decreas
fip
develop
lymphocyt
subset
tlymphocyt
markedli
decreas
cat
develop
fip
investig
whether
cell
count
recov
administr
antiftnfalpha
mab
tlymphocyt
count
decreas
day
viru
inocul
cat
group
b
fig
c
count
continu
decreas
develop
fip
cat
group
contrast
tlymphocyt
count
cat
no
recov
previru
inocul
level
administr
mab
cat
develop
fip
chang
bodi
temperatur
bodi
weight
fipv
inocul
measur
fig
fever
develop
fipv
inocul
group
b
cat
develop
fip
cat
no
high
bodi
temperatur
persist
develop
fip
contrast
although
high
bodi
temperatur
persist
cat
day
fipv
inocul
fever
observ
thereaft
bodi
temperatur
variat
stabil
day
fipv
inocul
thereaft
signific
differ
note
bodi
weight
group
b
day
fipv
inocul
fig
bodi
weight
continu
decreas
cat
develop
fip
cat
no
contrast
although
weight
loss
note
day
fipv
inocul
bodi
weight
slightli
increas
day
cat
cat
no
clinic
sign
listless
loss
appetit
observ
day
fipv
inocul
group
improv
group
b
administr
mab
anim
euthan
becam
critic
condit
reach
human
endpoint
group
anim
euthan
day
fipv
inocul
accordingli
surviv
decreas
zero
fig
group
b
one
anim
euthan
day
howev
cat
no
develop
clinic
sign
thereaft
surviv
day
human
molecular
target
therapi
perform
treat
infecti
diseas
immunemedi
diseas
tumor
mitsuya
et
al
tracey
et
al
hainsworth
target
therapi
capabl
exhibit
strong
therapeut
effect
minim
advers
reaction
target
factor
involv
diseas
target
therapi
perform
veterinari
field
molecular
target
drug
prepar
treat
intract
diseas
cat
present
studi
investig
whether
antibodi
neutral
tnfalpha
fip
pathologyaggrav
factor
actual
exhibit
therapeut
effect
cat
develop
fip
ie
antibodi
therapi
target
tnfalpha
perform
cat
fip
improv
symptom
investig
antiftnfalpha
mab
administ
day
cat
inocul
fipv
strain
highli
pathogen
fipv
chosen
reason
high
probabl
induc
fip
use
fipv
strain
may
import
reduc
number
anim
use
perform
experi
reliabl
induc
fip
fewer
type
fipvinocul
cat
develop
fip
previou
experi
type
fipv
strain
oral
subcutan
intraperiton
administ
incid
fip
unpublish
data
respect
suggest
type
fipv
use
incid
stabl
therapeut
effect
accur
judg
may
also
difficult
reproduc
fip
develop
challeng
field
fecal
materi
deriv
cat
type
fip
point
remain
investig
previou
experi
tnfalpha
vegf
agp
level
measur
plasma
collect
time
signific
increas
note
factor
day
fipv
inocul
furthermor
clinic
sign
fever
listless
jaundic
develop
day
fipv
inocul
group
time
administr
mab
base
comprehens
judgment
find
use
mous
mab
placebo
would
necessari
confirm
affect
viru
felin
tissu
immun
system
sinc
mous
mab
avail
use
solvent
antiftnfalpha
mab
pb
placebo
sinc
singl
administr
antiftnfalpha
mab
caus
advers
reaction
mab
consid
use
pb
placebo
appropri
progress
fip
prevent
cat
treat
mab
wherea
cat
develop
fip
placebo
control
group
mab
cat
plasma
vegf
level
improv
administr
antibodi
lymphocyt
count
also
recov
addit
plasma
agp
level
exceed
diagnost
criterion
fip
addi
et
al
observ
day
placebo
group
wherea
level
significantli
lower
mab
treat
cat
fact
strongli
suggest
mab
allevi
fip
symptom
inhibit
tnfalpha
activ
suggest
fipvspecif
tlymphocyt
contribut
viru
elimin
de
grootmijn
et
al
previous
report
tnfalpha
produc
fipvinfect
macrophag
effici
induc
apoptosi
tlymphocyt
particularli
tlymphocyt
takano
et
al
present
studi
decreas
number
tlymphocyt
note
day
fipv
inocul
recov
cat
treat
mab
tnfalphainduc
apoptosi
tlymphocyt
may
reduc
mab
ie
cellular
immun
respons
fipv
may
induc
maintain
variou
drug
treat
fip
investig
sinc
fip
viral
diseas
treatment
antivir
agent
antifipv
drug
examin
hartmann
ritz
hand
treatment
antiinflammatori
drug
repres
steroid
also
test
fip
inflammatori
diseas
howev
exist
antifipv
antiinflammatori
drug
transient
improv
fip
symptom
improv
surviv
time
qualiti
life
hartmann
ritz
mab
improv
surviv
time
qualiti
life
cat
fip
howev
one
mab
cat
develop
fip
thu
investig
necessari
determin
applic
therapeut
drug
fip
consid
combin
antifipv
drug
mab
improv
therapeut
effect
fip
therapeut
effect
combin
antitnfalpha
antibodi
antihsv
drug
hsv
infect
previous
report
high
boivin
et
al
regard
hsv
infect
antihsv
drug
acyclovir
target
factor
essenti
viral
replic
develop
type
drug
recent
develop
fipv
futur
studi
expect
hsieh
et
al
treatment
fip
combin
drug
warrant
investig
present
studi
administ
mous
monoclon
antibodi
mab
cat
symptom
improv
howev
may
necessari
investig
multipl
administr
mous
mab
cat
therapeut
effect
temporarili
exhibit
note
cat
sinc
administr
mous
mab
lead
antimous
mab
respons
cat
may
caus
anaphylact
reaction
advers
effect
reduct
therapeut
effect
shorten
halflif
second
administr
mous
mab
umehashi
et
al
report
administr
mab
constant
region
convert
felin
form
mousefelin
chimer
antibodi
induc
anaphylact
reaction
base
find
modifi
mab
mousefelin
chimer
antibodi
evalu
effect
furthermor
need
prepar
fabfrag
remov
fc
portion
mab
conclus
result
present
studi
suggest
antifelin
tnfalpha
mab
effect
treatment
fip
vivo
modif
mab
mousefelin
chimer
antibodi
therapeut
effect
combin
antifipv
agent
need
examin
detail
aim
applic
effect
therapeut
drug
fip
